116 related articles for article (PubMed ID: 18438330)
1. Statement 6: patients who are unresponsive to GH therapy should be given a trial of IGF-I.
Hardin DS
Pediatr Endocrinol Rev; 2008 Apr; 5 Suppl 3():857-60. PubMed ID: 18438330
[No Abstract] [Full Text] [Related]
2. Statement 5: the first line of treatment for children with idiopathic short stature (ISS) and low serum insulin-like growth factor-I (IGF-I) should be IGF-I.
Backeljauw P
Pediatr Endocrinol Rev; 2008 Apr; 5 Suppl 3():853-6. PubMed ID: 18438329
[No Abstract] [Full Text] [Related]
3. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
Laron Z
Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-I (lGF-l): safety and efficacy.
Laron Z
Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():78-85. PubMed ID: 16456486
[TBL] [Abstract][Full Text] [Related]
5. IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function.
Scheinowitz M; Feinberg MS; Laron Z
Growth Horm IGF Res; 2009 Jun; 19(3):280-2. PubMed ID: 19117781
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and therapeutic advances in growth hormone insensitivity.
David A; Metherell LA; Clark AJ; Camacho-Hübner C; Savage MO
Endocrinol Metab Clin North Am; 2005 Sep; 34(3):581-95, viii. PubMed ID: 16085161
[TBL] [Abstract][Full Text] [Related]
7. Long-term IGF-I treatment of children with Laron syndrome increases adiposity.
Laron Z; Ginsberg S; Lilos P; Arbiv M; Vaisman N
Growth Horm IGF Res; 2006 Feb; 16(1):61-4. PubMed ID: 16442822
[TBL] [Abstract][Full Text] [Related]
8. Statement 3: a low serum IGF-I Level in idiopathic short stature patients indicates partial GH insensitivity.
Bang P
Pediatr Endocrinol Rev; 2008 Apr; 5 Suppl 3():841-6. PubMed ID: 18438327
[No Abstract] [Full Text] [Related]
9. Biphasic response of subscapular skinfold thickness to hGH or IGF-1 administration to patients with congenital IGHD, congenital MPHD and Laron syndrome.
Bisker-Kassif O; Kauli R; Lilos P; Laron Z
Obes Res Clin Pract; 2014; 8(1):e55-62. PubMed ID: 24548577
[TBL] [Abstract][Full Text] [Related]
10. IGF-I treatment of patients with Laron syndrome suppresses serum thrombopoietin levels but does not affect serum erythropoietin.
Orit S; Joanne Y; Meira Z; Hannah T; Zvi L
Am J Hematol; 2009 Jan; 84(1):64. PubMed ID: 19021123
[No Abstract] [Full Text] [Related]
11. NREM sleep architecture and relation to GH/IGF-1 axis in Laron syndrome.
Verrillo E; Bizzarri C; Cappa M; Bruni O; Pavone M; Cutrera R
Horm Res Paediatr; 2010; 73(5):414-9. PubMed ID: 20389115
[TBL] [Abstract][Full Text] [Related]
12. Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders.
Savage MO; Attie KM; David A; Metherell LA; Clark AJ; Camacho-Hübner C
Nat Clin Pract Endocrinol Metab; 2006 Jul; 2(7):395-407. PubMed ID: 16932322
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age.
Cutfield WS; Lundgren F
Horm Res; 2009 Jan; 71 Suppl 1():39-45. PubMed ID: 19153504
[TBL] [Abstract][Full Text] [Related]
14. Insulinlike growth factor I affects ocular development: a study of untreated and treated patients with Laron syndrome.
Bourla DH; Laron Z; Snir M; Lilos P; Weinberger D; Axer-Siegel R
Ophthalmology; 2006 Jul; 113(7):1197.e1-5. PubMed ID: 16815402
[TBL] [Abstract][Full Text] [Related]
15. Postprandial hyperglycemia corrected by IGF-I (Increlex®) in Laron syndrome.
Latrech H; Simon A; Beltrand J; Souberbielle JC; Belmejdoub G; Polak M
Horm Res Paediatr; 2012; 78(3):193-200. PubMed ID: 22986916
[TBL] [Abstract][Full Text] [Related]
16. Development and biological function of the female gonads and genitalia in IGF-I deficiency -- Laron syndrome as a model.
Laron Z
Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():188-91. PubMed ID: 16641857
[TBL] [Abstract][Full Text] [Related]
17. [Hormones and osteoporosis update. Growth hormone and bone].
Tanaka H
Clin Calcium; 2009 Jul; 19(7):984-9. PubMed ID: 19567995
[TBL] [Abstract][Full Text] [Related]
18. Comparison between weight-based and IGF-I-based growth hormone (GH) dosing in the treatment of children with GH deficiency and influence of exon 3 deleted GH receptor variant.
Marchisotti FG; Jorge AA; Montenegro LR; Berger K; de Carvalho LR; Mendonca BB; Arnhold IJ
Growth Horm IGF Res; 2009 Apr; 19(2):179-86. PubMed ID: 19036620
[TBL] [Abstract][Full Text] [Related]
19. IGF-I and GH: potential use in gene doping.
Harridge SD; Velloso CP
Growth Horm IGF Res; 2009 Aug; 19(4):378-82. PubMed ID: 19487147
[TBL] [Abstract][Full Text] [Related]
20. [Laron type dwarfism].
Okimura Y
Nihon Rinsho; 2006 May; Suppl 1():94-7. PubMed ID: 16776102
[No Abstract] [Full Text] [Related]
[Next] [New Search]
